Probiotic Composition Modulating Gut Microbiota for CKD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic kidney disease (CKD) progression is exacerbated by gut dysbiosis and the accumulation of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which current treatments are unable to effectively manage.
Innovation Solution
A probiotic composition comprising Lactiplantibacillus plantarum subsp. plantarum MFM 30-3, either alone or in combination with other probiotic organisms, is administered to subjects to modulate the gut microbiota, reduce uremic toxin production, and improve renal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If oral adsorbents are applied to decrease absorption of uremic toxins, then uremic toxin levels are reduced, but treatment limitations and disadvantages remain
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus and Bifidobacterium species) as intermediary organisms that metabolize uremic toxin precursors in the gut. These probiotics act as mediators between the harmful toxins and the host, converting indole and p-cresol into less harmful compounds through bacterial metabolism, thereby reducing toxin absorption without relying on adsorbent materials
Solution Approach 2:
The patent replaces the mechanical/physical approach of oral adsorbents with a biological approach using probiotic microorganisms. Instead of using adsorbent materials to physically bind toxins, the invention employs bacterial enzymes and metabolic pathways to chemically transform toxin precursors, substituting a biological system for a mechanical one
2Object-affected harmful factors
If hemodialysis or kidney transplantation is performed to increase clearance of uremic toxins, then toxin removal is enhanced, but treatment limitations and disadvantages persist
Solution Approach 1:
The patent enables the patient's own gastrointestinal system to serve the function of toxin removal through probiotic colonization. The introduced probiotic bacteria establish themselves in the gut and continuously metabolize toxin precursors, allowing the body's natural digestive tract to perform the detoxification function that would otherwise require external dialysis machinery or transplantation
Solution Approach 2:
The patent extracts the toxin removal function from complex medical interventions (dialysis machines, transplantation surgery) and relocates it to the gastrointestinal ecosystem. By introducing probiotic bacteria that perform toxin metabolism locally in the gut, the invention separates the detoxification function from the complex clearance systems
3Object-affected harmful factors
If gut microbiota is modulated by increasing symbiotic bacteria, then uremic toxin production is reduced, but causality between CKD progression and gut dysbiosis is not completely understood
Solution Approach 1:
The patent applies preliminary action by introducing probiotic bacteria before significant gut dysbiosis and toxin accumulation occur. The probiotics are administered prophylactically to prevent the development of harmful microbial imbalances and toxin production, rather than attempting to correct established dysbiosis
Solution Approach 2:
The patent converts the harmful effect of gut microbiota (toxin production) into a beneficial effect by introducing probiotic strains that outcompete pathogenic bacteria. The same gastrointestinal environment that produces toxins becomes a site for beneficial microbial metabolism, transforming the harmful microbial function into a protective one
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The probiotic composition significantly improves kidney function by reducing kidney injury and fibrosis, decreasing oxidative stress and inflammation, and restoring gut homeostasis, thereby offering a potential preventive or therapeutic approach for CKD.
Implementation Method 1
The probiotic composition comprises Lactiplantibacillus plantarum subsp. plantarum MFM 30-3, either alone or in combination with one or more probiotic organisms
Implementation Method 2
The probiotic composition significantly improves kidney function by reducing kidney injury and fibrosis, decreasing oxidative stress and inflammation
Data Source
AI summary
An isolated bacterial strain of Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 deposited under the DSMZ Accession No. DSM 34213 is provided; a probiotic composition including an Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 and optionally, one or more additional probiotic organisms that enhance the probiotic activity of the Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 is also provided; and a method for preventing or treating chronic kidney disease in a subject in need thereof including: administering to the subject a pharmaceutically effective amount of the probiotic composition including an isolated bacterial strain of Lactiplantibacillus plantarum subsp. plantarum MFM 30-3, and optionally, one or more additional probiotic organisms that enhance the probiotic activity of the Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 is further provided.